Rechercher un essai clinique
Autre(s) option(s) de recherche
23 Résultat(s)
Essai en cours de recrutement = 
; Essai en cours = 
; Financé par un membre IRDiRC = 
; Membre d'un ERN = 
Essai(s) clinique(s) national(aux)
ALLEMAGNE
Berlin
ADDRESS: NOT PROVIDED - DE
An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of NeoGAA In Patients With Pompe Disease (Phase II-III) - DE
Institution: Information not provided - DE
AUTRICHE
WIEN
WIEN
COMET: A phase 3 randomized, multicenter, multinational, double-blinded study comparing the efficacy and safety of repeated biweekly infusions of neoGAA (GZ402666) and alglucosidase alfa in treatment-naïve patients with late onset Pompe disease (AT)
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Endokrinologie und Stoffwechsel
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
COMET: Etude de phase 3 randomisée, multicentrique, multinationale en double-aveugle comparant l'efficacité et la sécurité de perfusions répétées bihebdomadairement de NeoGAA (GZ402666) et d'alglucosidase alfa chez des patients non encore traités atteints de la forme tardive de la maladie de Pompe -BE
Erasme Hospital - ULB
Centre de Référence Neuromusculaire Erasme-HUDERF
BELGIQUE
VLAAMS BRABANT
LEUVEN
Étude ouverte, multicentrique et multinationale portant sur l'innocuité et la pharmacocinétique à long terme de perfusions répétées bihebdomadaires de NeoGAA chez des patients atteints de maladie de Pompe (phase II-III)
UZ Leuven - Campus Gasthuisberg
UZ Leuven
ESPAGNE
Andalucía
CÁDIZ
COMET: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatmentnaïve Patients with Late-onset Pompe Disease - ES
Hospital Universitario Puerta del Mar
Unidad clínica de Neurología y Neurofisiología
ESPAGNE
Cataluña
BARCELONA
COMET: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatmentnaïve Patients with Late-onset Pompe Disease - ES
Hospital de la Santa Creu i Sant Pau
Servicio de Neurología
ESPAGNE
Cataluña
ESPLUGUES DE LLOBREGAT
COMET: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatmentnaïve Patients with Late-onset Pompe Disease - ES
Hospital Sant Joan de Déu Barcelona
Servicio de Neurología
ESPAGNE
Comunidad Valenciana
VALENCIA
COMET: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatmentnaïve Patients with Late-onset Pompe Disease - ES
Hospital Universitario y Politécnico La Fe
Servicio de Neurología
ESPAGNE
Madrid
MADRID
COMET: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatmentnaïve Patients with Late-onset Pompe Disease - ES
Hospital Universitario La Paz
Servicio de Neurología
ETATS-UNIS
Washington
ADDRESS: NOT PROVIDED - US
COMET: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-naïve Patients With Late-onset Pompe Disease - GB
Institution: Information not provided - US
FRANCE
ILE-DE-FRANCE
PARIS
Etude d'extension en ouvert, multicentrique, internationale évaluant la tolérance sur le long-terme et la pharmacocinétique de perfusions répétées de NeoGAA toutes les deux semaines chez des patients atteints de la maladie de Pompe (Phase II-III) - FR
Institut de Myologie - Hôpital Pitié-Salpêtrière
Unité clinique de pathologie neuromusculaire
ROYAUME-UNI
Tyne & Wear
NEWCASTLE-UPON-TYNE
An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of NeoGAA In Patients With Pompe DiseasE - GB
Newcastle University
Newcastle Clinical Trials Unit
AUTRICHE
WIEN
ADDRESS: NOT PROVIDED - AT
PROPEL Study: A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease Compared With Alglucosidase Alfa/Placebo - AT
Institution: Information not provided - AT
AUTRICHE
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease - AT
Institution: Information not provided - AT
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
GLYCO-1B: Évaluation de l'innocuité et de l'efficacité de l'administration d'Empagliflozine en tant que traitement de la neutropénie chez des patients présentant une glycogénose de type 1b et déficients en G6PC3
Cliniques universitaires Saint-Luc - UCLouvain
Cliniques Universitaires Saint-Luc
BELGIQUE
VLAAMS BRABANT
LEUVEN
PROPEL Study: A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease Compared With Alglucosidase Alfa/Placebo - BE
UZ Leuven - Campus Gasthuisberg
Dienst neurologie/ Department of Neurology
ESPAGNE
Cataluña
BARCELONA
A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease - ES
Hospital de la Santa Creu i Sant Pau
Servicio de Neurología
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Glucose-6-Phosphatase (G6Pase) in Adults with Glycogen Storage Disease Type Ia (GSDIa) - ES
Institution: Information not provided - ES
ETATS-UNIS
North Carolina
DURHAM
A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy (Phase 1/2) - US
Duke University Medical Center
Division of Pediatrics-Medical Genetics
ETATS-UNIS
North Carolina
DURHAM
NEO-EXT: An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of NeoGAA In Patients With Pompe Disease (Phase II - III) - US
Duke University Medical Center
Essai(s) clinique(s) multinational(aux)
ETATS-UNIS
Washington
ADDRESS: NOT PROVIDED - US
COMET: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-naïve Patients With Late-onset Pompe Disease
Institution: Information not provided - US
ROYAUME-UNI
Greater London
LONDON
A Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Patients With McArdle Disease (Glycogen Storage Disorder 5)
MRC Centre for Neuromuscular Diseases
ETATS-UNIS
New Jersey
CRANBURY